+

WO1999009967A3 - Therapie hypocholesterolemiante - Google Patents

Therapie hypocholesterolemiante Download PDF

Info

Publication number
WO1999009967A3
WO1999009967A3 PCT/US1998/017459 US9817459W WO9909967A3 WO 1999009967 A3 WO1999009967 A3 WO 1999009967A3 US 9817459 W US9817459 W US 9817459W WO 9909967 A3 WO9909967 A3 WO 9909967A3
Authority
WO
WIPO (PCT)
Prior art keywords
cholesterol level
average
density lipoprotein
cholesterol
lipoprotein cholesterol
Prior art date
Application number
PCT/US1998/017459
Other languages
English (en)
Other versions
WO1999009967B1 (fr
WO1999009967A2 (fr
Inventor
Edwin J Whitney
Geraldine Mantell
Original Assignee
Merck & Co Inc
Edwin J Whitney
Geraldine Mantell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9814415.7A external-priority patent/GB9814415D0/en
Priority claimed from GBGB9815851.2A external-priority patent/GB9815851D0/en
Application filed by Merck & Co Inc, Edwin J Whitney, Geraldine Mantell filed Critical Merck & Co Inc
Priority to CA002300165A priority Critical patent/CA2300165A1/fr
Priority to EP98943329A priority patent/EP1007019A2/fr
Priority to AU91153/98A priority patent/AU9115398A/en
Publication of WO1999009967A2 publication Critical patent/WO1999009967A2/fr
Publication of WO1999009967A3 publication Critical patent/WO1999009967A3/fr
Publication of WO1999009967B1 publication Critical patent/WO1999009967B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes de prévention ou de réduction du risque d'un premier accident cardio-vasculaire, à l'aide d'un inhibiteur de HMG-CoA-réductase seul ou en combinaison avec un autre agent modifiant les lipides. Les sujets à traiter sont ceux qui présentent un taux de cholestérol total sérique moyen, un taux sérique de cholestérol dans les lipoprotéines de basse densité moyen à légèrement élevé et un taux sérique de cholestérol dans les lipoprotéines de haute densité en dessous de la moyenne, sans antécédents de maladies coronariennes cliniquement déclarées.
PCT/US1998/017459 1997-08-26 1998-08-21 Therapie hypocholesterolemiante WO1999009967A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002300165A CA2300165A1 (fr) 1997-08-26 1998-08-21 Therapie hypocholesterolemiante
EP98943329A EP1007019A2 (fr) 1997-08-26 1998-08-21 Therapie hypocholesterolemiante
AU91153/98A AU9115398A (en) 1997-08-26 1998-08-21 Cholesterol-lowering therapy

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US5696697P 1997-08-26 1997-08-26
US60/056,966 1997-08-26
US7685998P 1998-03-05 1998-03-05
US60/076,859 1998-03-05
US8536098P 1998-05-13 1998-05-13
US60/085,360 1998-05-13
GB9814415.7 1998-07-03
GBGB9814415.7A GB9814415D0 (en) 1998-07-03 1998-07-03 Cholesterol-lowering therapy
GB9815851.2 1998-07-21
GBGB9815851.2A GB9815851D0 (en) 1998-07-21 1998-07-21 Cholesterol-lowering therapy

Publications (3)

Publication Number Publication Date
WO1999009967A2 WO1999009967A2 (fr) 1999-03-04
WO1999009967A3 true WO1999009967A3 (fr) 1999-05-20
WO1999009967B1 WO1999009967B1 (fr) 1999-07-08

Family

ID=27517467

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/017459 WO1999009967A2 (fr) 1997-08-26 1998-08-21 Therapie hypocholesterolemiante

Country Status (4)

Country Link
EP (1) EP1007019A2 (fr)
AU (1) AU9115398A (fr)
CA (1) CA2300165A1 (fr)
WO (1) WO1999009967A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246894T3 (es) 1999-08-30 2006-03-01 Sanofi-Aventis Deutschland Gmbh Ramipril para la prevencion de sucesos cardiovasculares.
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156422A0 (en) 2001-01-26 2004-01-04 Schering Corp The use of substituted azetidinone compounds for the treatment of sitosterolemia
CA2563051A1 (fr) 2001-01-26 2002-08-01 Schering Corporation Combinaisons d'au moins un activateur de recepteurs actives de la proliferation des peroxysomes et d'au moins un inhibiteur de l'absorption des sterols, et traitements de troublesvasculaires
ATE345793T1 (de) 2001-09-21 2006-12-15 Schering Corp Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
WO2004043456A1 (fr) 2002-11-06 2004-05-27 Schering Corporation Inhibiteurs d'absorption du cholesterol pour le traitement de la demyelination
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
ES2318274T3 (es) 2003-03-07 2009-05-01 Schering Corporation Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia.
ATE406364T1 (de) 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0461548A2 (fr) * 1990-06-11 1991-12-18 E.R. SQUIBB & SONS, INC. Procédé pour empêcher une deuxième crise cardiaque utilisant un inhibiteur de l'enzyme HMG-CoA
EP0528515A2 (fr) * 1991-06-04 1993-02-24 Merck & Co. Inc. Inhibiteurs de réductase de HMG-CoA dans la prévention de la resténose après angioplastic coronaire
EP0671171A1 (fr) * 1994-01-18 1995-09-13 Bristol-Myers Squibb Company Utilisation d'inhibiteurs de la HMG CoA, réductase dans la fabrication d'un médicament pour réduire ou prevenir les risques d'attaques cardiaques
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0461548A2 (fr) * 1990-06-11 1991-12-18 E.R. SQUIBB & SONS, INC. Procédé pour empêcher une deuxième crise cardiaque utilisant un inhibiteur de l'enzyme HMG-CoA
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
EP0528515A2 (fr) * 1991-06-04 1993-02-24 Merck & Co. Inc. Inhibiteurs de réductase de HMG-CoA dans la prévention de la resténose après angioplastic coronaire
EP0671171A1 (fr) * 1994-01-18 1995-09-13 Bristol-Myers Squibb Company Utilisation d'inhibiteurs de la HMG CoA, réductase dans la fabrication d'un médicament pour réduire ou prevenir les risques d'attaques cardiaques

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
HARIA M. ET AL: "Pravastatin: A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease.", DRUGS, (1997) 53/2 (299-336). REFS: 267 ISSN: 0012-6667 CODEN: DRUGAY, New Zealand, XP002095845 *
KELLICK K A ET AL: "Outcome monitoring of fluvastatin in a Department of Veterans Affairs lipid clinic.", AMERICAN JOURNAL OF CARDIOLOGY, (1995 JUL 13) 76 (2) 62A-64A. JOURNAL CODE: 3DQ. ISSN: 0002-9149., United States, XP002095843 *
MARCUS A.: "Role of the HMG-CoA reductase inhibitors in the treatment of dyslipidemia An evolutionary review.", CARDIOVASCULAR REVIEWS AND REPORTS, (1996) 17/1 (10-11+15-16+21-24+26-27) ISSN: 0197-3118 CODEN: CRRPD4, United States, XP002095841 *
MEISER, B. M. ET AL: "Simvastatin decreases accelerated graft vessel disease (GVD) after heart transplantation in an animal model", TRANSPLANT. PROC. (1993), 25(2), 2077-9 CODEN: TRPPA8;ISSN: 0041-1345, XP002095842 *
MOTOMURA N. ET AL: "HMG-CoA reductase inhibitors in organ transplantation.", JOURNAL OF NEPHROLOGY, (1997) 10/2 (68-76). REFS: 127 ISSN: 1121-8428 CODEN: JLNEEL, Italy, XP002095844 *
PFEIFER M.A. ET AL: "Cholesterol and recurrent events: A secondary prevention trial for normolipidemic patients.", AMERICAN JOURNAL OF CARDIOLOGY, (1995) 76/9 (98C-106C). ISSN: 0002-9149 CODEN: AJCDAG, United States, XP000579209 *
PROBSTFIELD, JEFFREY L. (1) ET AL: "Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study.", AMERICAN JOURNAL OF CARDIOLOGY, (1995) VOL. 76, NO. 9, PP. 47C-53C. ISSN: 0002-9149., XP002095840 *
SOUTHWORTH M R ET AL: "The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients.", ANNALS OF PHARMACOTHERAPY, (1997 APR) 31 (4) 489-91. REF: 32 JOURNAL CODE: BBX. ISSN: 1060-0280., United States, XP002095847 *
STEIN E. ET AL: "Cerivastatin, a new potent synthetic HMG Co-A reductase inhibitor: Effect of 0.2 mg daily in subjects with primary hypercholesterolemia.", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, (1997) 2/1 (7-16). REFS: 30 ISSN: 1074-2484 CODEN: JCPTFE, United States, XP002095846 *

Also Published As

Publication number Publication date
WO1999009967B1 (fr) 1999-07-08
CA2300165A1 (fr) 1999-03-04
EP1007019A2 (fr) 2000-06-14
AU9115398A (en) 1999-03-16
WO1999009967A2 (fr) 1999-03-04

Similar Documents

Publication Publication Date Title
WO1999009967A3 (fr) Therapie hypocholesterolemiante
Eisenberg Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials
AU5074196A (en) Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
BR0013704A (pt) Uso de inibidores do sistema renina-angiotensina na prevenção de casos cardiovasculares
EP1238667A3 (fr) Utilisation des benzothiophènes pour le traitement de l'hypercholestérolemie
PL307463A1 (en) Pharmaceutical agent especially for inhibiting osteoporosis and lowering cholesterol level in blood serum
WO2000028981A3 (fr) Methodes de traitement, de prevention et de reduction du risque d'apparition de la maladie d'alzheimer utilisant un inhibiteur de la hmg-coa reductase
AU5691198A (en) Nonwoven web laminate having relatively hydrophilic zone and related method for its manufacture
WO1999066031A3 (fr) Preparation pharmaceutique a base d'un facteur vii
WO2001015676A3 (fr) Compositions et methodes permettant de moduler le taux de hdl cholesterol et de triglycerides
CA2268439A1 (fr) Extrait d'ecorce de citrus utilise en tant qu'inhibiteur de 3-hydroxy-3-methyl-glutaryl coenzyme a (hmg coa) reductase
WO1998051289A3 (fr) Monoesters de probucol destines au traitement de troubles cardio-vasculaires et inflammatoires
AU9040098A (en) Compounds and method for the prevention and treatment of diabetic retinopathy
AU2174197A (en) Amphipathic molecules as cholesterol and other lipid uptake inhibitors
EP0713706A3 (fr) Agent abaissant le lipoprotéine (a), agent abaissant le cholestérol et médicaments contenant ces agents
WO2002072104A3 (fr) Traitement combine a l'aide d'un agent antihypertenseur et d'un inhibiteur de l'absorption du cholesterol
EP0989852A4 (fr) Methode de traitement de l'atherosclerose a l'aide d'un inhibiteur de mpt et de medicaments reduisant le cholesterol
AU2003291206A1 (en) Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease
WO2000069445A8 (fr) Polytherapie pour traiter l'hypercholesterolemie
WO2001041754A3 (fr) Inhibiteurs d'agregation plaquettaire induite par le collagene
Hunninghake Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy
BG105471A (en) Method for preventing or delaying the need for a catheter of the coronary artery
AU5544994A (en) Use of 17alpha-dihydroequilenin for lowering cholesterol
Campeau Lipid lowering and coronary bypass graft surgery
Smith Jr Review of recent clinical trials of lipid lowering in coronary artery disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: B1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2300165

Country of ref document: CA

Ref country code: CA

Ref document number: 2300165

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998943329

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 91153/98

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1998943329

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998943329

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载